Brusilovsky M, Bao R, Rochman M, et al. Host-Microbiota Interactions in the Esophagus During Homeostasis and Allergic Inflammation. Gastroenterology 2022;162:521-534 e8. doi: 10.1053/j.gastro.2021.10.002

Kurten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, Reeder C, Lang S, Chen X, Duvvuri U, Kim S, Liu A, Tabib T, Lafyatis R, Feng J, Gao SJ, Bruno TC, Vignali DAA, Lu X, Bao R, Vujanovic L, Ferris RL. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021;12(1):7338. Epub 2021/12/19. doi: 10.1038/s41467-021-27619-4.

Brusilovsky M, Bao R, Rochman M, Kemter AM, Nagler CR, Rothenberg ME. Host-Microbiota Interactions in the Esophagus During Homeostasis and Allergic Inflammation. Gastroenterology. 2021. Epub 2021/10/11. doi: 10.1053/j.gastro.2021.10.002.

Bao R, Spranger S, Hernandez K, Zha Y, Pytel P, Luke JJ, Gajewski TF, Volchenboum SL, Cohn SL, Desai AV. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer. 2021 Jul;9(7):e002417. DOI: 10.1136/jitc-2021-002417.

Bao R, Hesser LA, He Z, Zhou X, Nadeau KC, Nagler CR. Fecal Microbiome and Metabolome Differ in Healthy and Food-Allergic Twins. J Clin Invest. 2021;131(2). Epub 2021/01/20. https://doi.org/10.1172/JCI141935.

Bao R, Stapor D, Luke JJ. Molecular Correlates and Therapeutic Targets in T Cell-Inflamed Versus Non-T Cell-Inflamed Tumors Across Cancer Types. Genome Med. 2020;12(1):90. Epub 2020/10/28. https://doi.org/10.1186/s13073-020-00787-6.

Bao R, Surriga O, Olson DJ, Allred JB, Strand CA, Zha Y, Carll T, Labadie BW, Bastos BR, Butler M, Hogg D, Musi E, Ambrosini G, Munster P, Schwartz GK, Luke JJ. Transcriptional Analysis of Metastatic Uveal Melanoma Survival Nominates NRP1 as a Therapeutic Target. Melanoma Res. 2021;31(1):27-37. Epub 2020/11/11. https://doi.org/ 10.1097/CMR.0000000000000701.

Bao R, Hernandez K, Huang L, Luke JJ. ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19. J Immunother Cancer. 2020;8(2). Epub 2020/07/18. https://doi.org/10.1136/jitc-2020-001020.

Labadie BW, Liu P, Bao R, Crist M, Fernandes R, Ferreira L, Graupner S, Poklepovic AS, Duran I, Vareki SM, Balar AV, Luke JJ. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. Journal of Translational Medicine 2019;17:386. https://doi.org/10.1186/s12967-019-02144-7.

Bao R, Onishi KG, Tolla E, Ebling FJP, Lewis JE, Anderson RL, Barrett P, Prendergast BJ, Stevenson TJ. Genome sequencing and transcriptome analyses of the Siberian hamster hypothalamus identify mechanisms for seasonal energy balance. Proc Natl Acad Sci USA 2019;116:13116. https://doi.org/10.1073/pnas.1902896116.

Feehley T*, Plunkett CH*, Bao R*, Choi Hong SM, Culleen E, Belda-Ferre P, Campbell E, Aitoro R, Nocerino R, Paparo L, Andrade J, Antonopoulos DA, Berni Canani R, Nagler CR. Healthy infants harbor intestinal bacteria that protect against food allergy. Nat Med. 2019;25(3):448-53. doi: 10.1038/s41591-018-0324-z.

Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res 2019;25:3074. https://doi.org/10.1158/1078-0432.CCR-18-1942.

Matson V*, Fessler J*, Bao R*, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science 2018;359:104. https://doi.org/10.1126/science.aao3290.

Spranger S*, Luke JJ*, Bao R, Zha Y, Hernandez KM, Li Y, Gajewski AP, Andrade J, Gajewski TF. Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci USA 2016;113:E7759. https://doi.org/10.1073/pnas.1609376113.

Shah S, Ward JE, Bao R, Hall CR, Brockstein BE, Luke JJ. Clinical Response of a Patient to Anti–PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors. Cancer Immunol Res 2016;4:903. https://doi.org/10.1158/2326-6066.CIR-16-0087.

Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM, Investigators K-. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399(10336):1718-29. Epub 2022/04/04. doi: 10.1016/S0140-6736(22)00562-1. PubMed PMID: 35367007.

Davar D, Zappasodi R, Wang H, Naik GS, Sato T, Bauer T, Bajor D, Rixe O, Newman W, Qi J, Holland A, Wong P, Sifferlen L, Piper D, Sirard CA, Merghoub T, Wolchok JD, Luke JJ. Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022;28(18):3990-4002. Epub 2022/05/03. doi: 10.1158/1078-0432.CCR-22-0339.

Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Phase I Study of Stereotactic Body Radiotherapy Plus Nivolumab and Urelumab or Cabiralizumab in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021 Jun 24:clincanres.0810.2021. DOI: 10.1158/1078-0432.CCR-21-0810

Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021 May 4:JCO2100079. DOI: 10.1200/JCO.21.00079

Luke JJ, Barlesi F, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, Cassier PA, Khasraw M, Kindler HL, Fang H, Fan F, Allaire K, Patel M, Ye S, Chao DT, Henner WR, Hayflick JS, McDevitt MA, Fong L. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021;9(2). Epub 2021/02/21. https://doi.org/10.1136/jitc-2020-002015.

Luke JJ*, Onderdonk BE*, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020;26(24):6437-44. Epub 2020/10/09. https://doi.org/10.1158/1078-0432.CCR-20-1790.

Luke JJ*, Olson DJ*, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, Hogg O, Munster PN, Schwartz GK. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clin Cancer Res. 2020;26:804. https://doi.org/10.1158/1078-0432.CCR-19-1223.

Luke JJ*, Lemons JM*, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018;36:1611–8. https://doi.org/10.1200/JCO.2017.76.2229.

Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50. https://doi.org/10.1186/s40425-016-0152-y.

Luke JJ, Zha Y, Matijevich K, Gajewski TF. Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial. J Immunother Cancer. 2016;4:35. https://doi.org/10.1186/s40425-016-0140-2.

Luke JJ, Donahue H, Nishino M, Giobbie-Hurder A, Davis M, Bailey N, Ott PA, Hodi FS. Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. Cancer Immunol Res. 2015;3:986. https://doi.org/10.1158/2326-6066.CIR-15-0066.

Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie‐Hurder A, Lawrence, DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD. Clinical activity of ipilimumab for metastatic uveal melanoma. Cancer. 2013;119:3687–95. https://doi.org/10.1002/cncr.28282.

Luke JJ, D’Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Maki RG, De Stanchina E, Musi E, Singer S, Schwartz GK. The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial. Clin Cancer Res. 2012;18:2638. https://doi.org/10.1158/1078-0432.CCR-11-3203.

Augustin RC, Bao R, Luke JJ. Targeting Cbl-b in cancer immunotherapy. Journal for ImmunoTherapy of Cancer. 2023;11(2):e006007. doi: 10.1136/jitc-2022-006007

Eggermont AMM, Hamid O, Long GV, Luke JJ. Optimal systemic therapy for high-risk resectable melanoma. Nat Rev Clin Oncol. 2022;19(7):431-9. Epub 2022/04/27. doi: 10.1038/s41571-022-00630-4.

Augustin RC, Luke JJ. Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma. J Clin Oncol 2022:JCO2201770. doi: 10.1200/JCO.22.01770

Augustin RC, Leone RD, Naing A, Fong L, Bao R*, Luke JJ*. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. J Immunother Cancer. 2022;10(2). Epub 2022/02/10. https://doi.org/10.1136/jitc-2021-004089.

Buchanan T, Amouzegar A, Luke JJ. Next-Generation Immunotherapy Approaches in Melanoma. Curr Oncol Rep. 2021 Aug 3;23(10):116. https://doi.org/10.1007/s11912-021-01104-z.

Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. STING Agonists as Cancer Therapeutics. Cancers (Basel). 2021 May 30;13(11):2695. doi: 10.3390/cancers13112695

Garris CS, Luke JJ. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response. Clin Cancer Res. 2020;26(15):3901-7. Epub 2020/04/26. https://doi.org/10.1158/1078-0432.CCR-19-1321.

Poklepovic AS, Luke JJ. Considering adjuvant therapy for stage II melanoma. Cancer. 2020;126:1166–74. https://doi.org/10.1002/cncr.32585.

Labadie BW, Bao R, Luke JJ. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis. Clin Cancer Res. 2019;25:1462. https://doi.org/10.1158/1078-0432.CCR-18-2882.

Trujillo JA, Sweis RF, Bao R, Luke JJ. T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res. 2018;6:990. https://doi.org/10.1158/2326-6066.CIR-18-0277.

Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nature Reviews Clinical Oncology. 2017;14:463–82. https://doi.org/10.1038/nrclinonc.2017.43.

Bao R, Huang L, Andrade J, Tan W, Kibbe WA, Jiang H, Feng G. Review of Current Methods, Applications, and Data Management for the Bioinformatics Analysis of Whole Exome Sequencing. Cancer Informatics. January 2014. https://doi.org/10.4137/CIN.S13779.

Augustin RC, Bao R, Luke JJ. Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor Subclones. Clinical Cancer Research. 2023;29(3):505-50. doi: 10.1158/1078-0432.CCR-22-3022

Jameson-Lee M, Luke JJ. Ipilimumab Combination Dosing: Less is More. Clin Cancer Res. 2021 Aug 2;clincanres.2406.2021. DOI: 10.1158/1078-0432.CCR-21-2406.

Shoushtari AN, Bao R, Luke JJ. PD-1 Blockade in Chinese versus Western Patients with Melanoma. Clin Cancer Res. 2020;26(16):4171-3. Epub 2020/06/04. https://doi.org/10.1158/1078-0432.CCR-20-1558.

Luke JJ, Ascierto PA. Biology confirmed but biomarkers elusive in melanoma immunotherapy. Nature Reviews Clinical Oncology. 2020;17:198–9. https://doi.org/10.1038/s41571-020-0328-8.

Jameson-Lee M, Luke JJ. Moving toward multi-dimensional biomarkers in cancer immunotherapy. Chinese Clinical Oncology. Vol 9, No 6 (December 2020): Chinese Clinical Oncology 2020.

Luke JJ, Pal SK. Further evidence to support judicious use of antibiotics in patients with cancer. Annals of Oncology. 2018;29:1349–51. https://doi.org/10.1093/annonc/mdy153.